Effects of targeted graphene oxide loaded with atractylenolide-I on apoptosis and cell cycle of ovarian cancer cells

doi:10.12307/2021.063

Abstract

Abstract: BACKGROUND: Atractylolide I (AT-I) has a variety of pharmacological and biological activities, such as anti-inflammatory, anti-oxidation, and anti-tumor, but it has poor water solubility, light instability, low permeability, and low bioavailability.
OBJECTIVE: To prepare a novel AT-I vector targeting ovarian cancer cells and evaluate its physicochemical properties and biological activities.
METHODS: We functionalized graphene oxide (GO) to obtain arginine glycine aspartate-graphene oxide conjugated structure (RGD@GO), which is stable and biocompatible in a variety of biological solutions, then loaded with hydrophobic molecule AT-I. AT-I loaded RGD@GO nanoparticles (RGD@GO-AT-I) was prepared by emulsion solvent diffusion method. The drug loading and in vitro release properties of the nanoparticles were determined. The human ovarian cancer cell A2780 was co-cultured with GO-AT-I solution, RGD@GO-AT-I solution, RGD@GO solution, and AT-I solution, and co-culture with PBS was set as the control. Cell viability was detected by MTT method after 24 and 48 hours. Human ovarian cancer cell A2780 was co-cultured with GO-AT-I solution and RGD@GO-AT-I solution, and co-culture with PBS was set as the control. Cell cycle and apoptosis were detected after 48 hours of culture.
RESULTS AND CONCLUSION: (1) The highest drug load of RGD@GO-AT-I was (28.09±0.17)%; RGD@GO-AT-I showed a good drug release curve within 30 hours in vitro. (2) After culture for 24 and 48 hours, the cell survival rate of GO-AT-I group and RGD@GO-AT-I group was lower than that of control group (P < 0.01). The cell survival rate of RGD@GO-AT-I group was lower than that of GO-AT-I group (P < 0.01). (3) The proportion of cells in sub-G1 phase in GO-AT-I group and RGD@GO-AT-I group was higher than that in the control group (P < 0.01), and the proportion of cells in G0/G1 phase was lower than that in the control group (P < 0.01). The proportion of cells in the sub-G1 phase in RGD@GO-AT-I group was higher than that in GO-AT-I group (P < 0.01). The proportion of cells in G0/G1 phase was lower than that in GO-AT-I group (P < 0.01). (4) The apoptosis rates of GO-AT-I group and RGD@GO-AT-I group were higher than that of control group (P < 0.01). The apoptosis rate of RGD@GO-AT-I group was higher than that of GO-AT-I group (P < 0.01). (5) The results showed that targeting RGD@GO-AT-I inhibited cell proliferation by inhibiting the G0/G1 phase of A2780 cells and inducing apoptosis, and significantly enhanced the anti-cancer activity of AT-I.

Key words: materials, vector, graphene oxide, tumor, ovarian cancer, targeting, apoptosis, cell cycle

CLC Number:

Gan Fang. Effects of targeted graphene oxide loaded with atractylenolide-I on apoptosis and cell cycle of ovarian cancer cells[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(28): 4492-4496.

Figures/Tables 7

References

[1] HENDERSON JT, WEBBER EM, SAWAYA GF. Screening for ovarian Cancer: updated evidence report and systematic review for the us preventive services task force. JAMA. 2018;319:595-606.
[2] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2016. Cancer J Clin. 2016;66(1):7-30.
[3] VAUGHAN S, COWARD JI, BAST RC JR, et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer. 2011; 11(10):719-725.
[4] LI CQ, HE LC, DONG HY, et al. Screening for the anti-inflammatory activity of fractions and compounds from Atractylodes macrocephala koidz. J Ethnopharmacol. 2007;114(2):212-217.
[5] KISO Y, TOHKIN M, HIKINO H. Mechanism of antihepatotoxic activity of atractylenolide I: Effect on free radical generation and lipid peroxidation. Planta Med. 1985;(2):97-100.
[6] YU R, YU BX, CHEN JF, et al. Anti-tumor effects of Atractylenolide I on bladder cancer cells. J Exp Clin Cancer Res. 2016;35:40.
[7] YE Y, CHAO XJ, WU JF, et al. ERK/GSK3β signaling is involved in Atractylenolide I-induced apoptosis and cell cycle arrest in melanoma cells. Oncol Rep. 2015;34(3):1543-1548.
[8] LIU Y, JIA Z, DONG L, et al. A randomized pilot study of Atractylenolide I on gastric cancer cachexia patients. Evid Based Complement Alternat Med. 2008;5(3):337-344.
[9] LIU H, ZHANG G, HUANG J, et al. Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro. J Transl Med. 2016; 14(1):104.
[10] FU F, GU J, CAO J, et al. Reduction of silver ions using an alkaline cellulose dope: straightforward access to Ag/ZnO decorated cellulose nanocomposite film with enhanced antibacterial activities. ACS Sustain Chem Eng. 2018;6(1):738-748.
[11] VAN VEEN B, PAJANDER J, ZUURMAN, K, et al. The effect of powder blend and tablet structure on drug release mechanisms of hydrophobic starch acetate matrix tablets. Eur J Pharm Biopharm. 2005;61(3):149-157.
[12] DIMIEV A, KOSYNKIN DV, ALEMANY LB, et al. Pristine graphite oxide. J Am Chem Soc. 2012;134(5):2815-2822.
[13] LU AH, SALABAS EE, SCHÜTH F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed. 2007;46(8):1222-1244.
[14] YANG X, WANG Y, HUANG X, et al. Multi-functionalized graphene oxide based anticancer drug-carrier with dual-targeting function and pH-sensitivity. J Mater Chem. 2011;21(10):3448-3454.
[15] JIA PP, SUN T, JUNAID M, et al. Nanotoxicity of different sizes of graphene (G) and graphene oxide (GO) in vitro and in vivo. Environ Pollut. 2019;247:595-606.
[16] Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175-193.
[17] Yao Z, Yang X, Liu X, et al. Electrochemical quercetin sensor based on a nanocomposite consisting of magnetized reduced graphene oxide, silver nanoparticles and a molecularly imprinted polymer on a screen-printed electrode. Microchimica Acta. 2018;185(1):70.
[18] Tonelli FM, Goulart VA, Gomes KN, et al. Graphene-based nanomaterials: biological and medical applications and toxicity. Nanomed. 2015;10(15):2423-2450.
[19] Nezakati T, Cousins BG, Seifalian AM. Seifalian. Toxicology of chemically modified graphene-based materials for medical application. Arch Toxicol. 2014;88(11):1987-2012.
[20] Wang YR, Xu Y, Jiang ZZ, et al. Deoxypodophyllotoxin induces G2/M cell cycle arrest and apoptosis in SGC-7901 cells and inhibits tumor growth in vivo. Molecules. 2015;20(1):1661-1675.